Clinical evaluation shows high viral suppression rates in people with HIV using ISL+LEN, suggesting effective treatment.
ISL+LEN maintained high rates of VS, including in one participant with pre-existing M184V. No participants developed drug resistance. These findings support the ongoing evaluation of QW oral ISL+LEN for HIV-1 treatment.
No takes yet. Share an insight, caveat, or question.
VanderVeen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: